Causal relationship between Helicobacter pylori infection and childhood immune thrombocytopenia and influencing factors for prognosis

Xiao-Yang ZHOU, Mei YAN, Ying-Bin YUE, Hailigulli NURIDDIN, Xue-Mei WANG, Yong-Feng CHENG, Chun-Can WU, Yu LIU

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (9) : 1105-1112.

PDF(870 KB)
HTML
PDF(870 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (9) : 1105-1112. DOI: 10.7499/j.issn.1008-8830.2412180
CLINICAL RESEARCH

Causal relationship between Helicobacter pylori infection and childhood immune thrombocytopenia and influencing factors for prognosis

Author information +
History +

Abstract

Objective To investigate the causal relationship between Helicobacter pylori (Hp) infection and immune thrombocytopenia (ITP) using Mendelian randomization (MR), as well as the association between Hp infection and chronic ITP (cITP) through a clinical study. Methods The datasets from genome-wide association studies were used to select the single nucleotide polymorphism loci significantly associated with Hp infection as genetic instrumental variables. The MR analysis model was used to investigate the causal relationship between ITP and Hp infection. A retrospective analysis was conducted on the medical data of 316 children with newly diagnosed ITP at the First Affiliated Hospital of Xinjiang Medical University from January 2020 to December 2023. The children were followed up for 1 year, and a multivariate logistic regression analysis was used to investigate the risk factors for cITP. Results The inverse variance weighted analysis revealed that Hp infection was significantly associated with an increased risk of ITP (OR=1.280, 95%CI: 1.098-1.492, P=0.002). There was no heterogeneity or pleiotropy in this MR study (P>0.05), and the model was stable. The "leave-one-out" sensitivity analysis verified the reliability of the results. The multivariate logistic regression analysis demonstrated that Hp infection was an independent risk factor for progression to cITP (OR=7.916, 95%CI: 3.327-18.832, P<0.001). Conclusions Hp infection is a risk factor for the onset of ITP and is an independent risk factor for cITP in children.

Key words

Immune thrombocytopenia / Helicobacter pylori / Mendelian randomization / Clinical study / Child

Cite this article

Download Citations
Xiao-Yang ZHOU , Mei YAN , Ying-Bin YUE , et al . Causal relationship between Helicobacter pylori infection and childhood immune thrombocytopenia and influencing factors for prognosis[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(9): 1105-1112 https://doi.org/10.7499/j.issn.1008-8830.2412180

References

[1]
国家卫生健康委. 儿童原发性免疫性血小板减少症诊疗规范(2019年版)[J]. 全科医学临床与教育, 2019, 17(12): 1059-1062. DOI: 10.13558/j.cnki.issn1672-3686.2019.012.002 .
[2]
González-López TJ, Provan D, Bárez A, et al. Primary and secondary immune thrombocytopenia (ITP): time for a rethink[J]. Blood Rev, 2023, 61: 101112. DOI: 10.1016/j.blre.2023.101112 .
[3]
Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID[J]. Blood, 2022, 140(6): 542-555. DOI: 10.1182/blood.2020006480 .
[4]
Tinazzi E, Osti N, Beri R, et al. Pathogenesis of immune thrombocytopenia in common variable immunodeficiency[J]. Autoimmun Rev, 2020, 19(9): 102616. DOI: 10.1016/j.autrev.2020.102616 .
[5]
Wang L, Cao ZM, Zhang LL, et al. Helicobacter pylori and autoimmune diseases: involving multiple systems[J]. Front Immunol, 2022, 13: 833424. PMCID: PMC8866759. DOI: 10.3389/fimmu.2022.833424 .
[6]
Lv Y, Shi H, Liu H, et al. Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently?[J]. Front Immunol, 2022, 13: 953716. PMCID: PMC9393521. DOI: 10.3389/fimmu.2022.953716 .
[7]
何钰珊, 林熙, 杨婉婷, 等. 免疫性血小板减少症患儿生活质量研究进展[J]. 中国小儿血液与肿瘤杂志, 2021, 26(5): 310-313, 317. DOI: 10.3969/j.issn.1673-5323.2021.05.013 .
[8]
Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life[J]. Am J Hematol, 2021, 96(2): 199-207. PMCID: PMC7898815. DOI: 10.1002/ajh.26036 .
[9]
Shah SC, Iyer PG, Moss SF. Aga clinical practice update on the management of refractory Helicobacter pylori infection: expert review[J]. Gastroenterology, 2021, 160(5): 1831-1841. PMCID: PMC8281326. DOI: 10.1053/j.gastro.2020.11.059 .
[10]
常明珠, 李雨澎, 母润红, 等. 幽门螺杆菌检测方法及其应用价值的研究进展[J]. 吉林大学学报(医学版), 2023, 49(1): 253-260. DOI: 10.13481/j.1671-587X.20230134 .
[11]
Suerbaum S, Ailloud F. Genome and population dynamics during chronic infection with Helicobacter pylori [J]. Curr Opin Immunol, 2023, 82: 102304. DOI: 10.1016/j.coi.2023.102304 .
[12]
徐太军, 常友成. 幽门螺杆菌感染对机体糖代谢、脂代谢的影响[J]. 临床消化病杂志, 2023, 35(2): 141-144. DOI: 10.3870/lcxh.j.issn.1005-541X.2023.02.012 .
[13]
Ikuse T, Toda M, Kashiwagi K, et al. Efficacy of Helicobacter pylori eradication therapy on platelet recovery in pediatric immune thrombocytopenic purpura-case series and a systematic review[J]. Microorganisms, 2020, 8(10): 1457. PMCID: PMC7598273. DOI: 10.3390/microorganisms8101457 .
[14]
Ference BA, Holmes MV, Smith GD. Using Mendelian randomization to improve the design of randomized trials[J]. Cold Spring Harb Perspect Med, 2021, 11(7): a040980. PMCID: PMC8247560. DOI: 10.1101/cshperspect.a040980 .
[15]
Sekula P, Del Greco M F, Pattaro C, et al. Mendelian randomization as an approach to assess causality using observational data[J]. J Am Soc Nephrol, 2016, 27(11): 3253-3265. PMCID: PMC5084898. DOI: 10.1681/ASN.2016010098 .
[16]
Yuan S, Wang L, Zhang H, et al. Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases[J]. EBioMedicine, 2023, 89: 104488. PMCID: PMC9988426. DOI: 10.1016/j.ebiom.2023.104488 .
[17]
中华医学会儿科学分会消化学组, 《中华儿科杂志》编辑委员会. 儿童幽门螺杆菌感染诊治专家共识[J]. 中华儿科杂志, 2015, 53(7): 496-498. DOI: 10.3760/cma.j.issn.0578-1310.2015.07.006 .
[18]
史美龄, 周敏. 儿童原发性免疫性血小板减少症的慢性病程预测分析[J]. 中国小儿血液与肿瘤杂志, 2024, 29(1): 61-65. DOI: 10.3969/j.issn.1673-5323.2024.01.013 .
[19]
Schifferli A, Le Gavrian G, Aladjidi N, et al. Chronic refractory immune thrombocytopenia in adolescents and young adults[J]. Br J Haematol, 2023, 203(1): 36-42. DOI: 10.1111/bjh.19081 .
[20]
Pincez T, Fernandes H, Fahd M, et al. Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome[J]. Am J Hematol, 2024, 99(7): 1269-1280. DOI: 10.1002/ajh.27337 .
[21]
任颖, 谢萍. 儿童免疫性血小板减少症临床特征分析[J]. 中国实验血液学杂志, 2023, 31(5): 1443-1447. DOI: 10.19746/j.cnki.issn.1009-2137.2023.05.030 .
[22]
Lee A, Hong J, Chung H, et al. Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia[J]. Sci Rep, 2020, 10(1): 9370. PMCID: PMC7287131. DOI: 10.1038/s41598-020-66460-5 .
[23]
Fu H, Vuononvirta J, Fanti S, et al. The glucose transporter 2 regulates CD8+ T cell function via environment sensing[J]. Nat Metab, 2023, 5(11): 1969-1985. PMCID: PMC10663157. DOI: 10.1038/s42255-023-00913-9 .
[24]
Malik A, Sayed AA, Han P, et al. The role of CD8+ T-cell clones in immune thrombocytopenia[J]. Blood, 2023, 141(20): 2417-2429. PMCID: PMC10329190. DOI: 10.1182/blood.2022018380 .
[25]
Sabbagh P, Javanian M, Koppolu V, et al. Helicobacter pylori infection in children: an overview of diagnostic methods[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(6): 1035-1045. DOI: 10.1007/s10096-019-03502-5 .
[26]
许晶, 严倩, 李冬云, 等. 国内抗幽门螺杆菌治疗在儿童原发免疫性血小板减少症中疗效的Meta分析和试验序贯分析[J]. 中国医院药学杂志, 2020, 40(5): 552-558. DOI: 10.13286/j.1001-5213.2020.05.16 .
[27]
Zhang Z, Chen X, Li B, et al. Helicobacter pylori induces urease subunit B-specific CD8+ T cell responses in infected individuals via cytosolic pathway of cross-presentation[J]. Helicobacter, 2023, 28(5): e13005. DOI: 10.1111/hel.13005 .
[28]
Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance-from biology to clinical implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(9): 613-629. DOI: 10.1038/s41575-021-00449-x .
[29]
Eletto D, Mentucci F, Voli A, et al. Helicobacter pylori pathogen-associated molecular patterns: friends or foes?[J]. Int J Mol Sci, 2022, 23(7): 3531. PMCID: PMC8998707. DOI: 10.3390/ijms23073531 .
[30]
Wang X, Zhao G, Shao S, et al. Helicobacter pylori triggers inflammation and oncogenic transformation by perturbing the immune microenvironment[J]. Biochim Biophys Acta Rev Cancer, 2024, 1879(5): 189139. DOI: 10.1016/j.bbcan.2024.189139 .
[31]
Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection[J]. Helicobacter, 2017,22 :e12403. DOI: 10.1111/hel.12403 .
Suppl 1
[32]
Schuetz AN, Theel ES, Cole NC, et al. Testing for Helicobacter pylori in an era of antimicrobial resistance[J]. J Clin Microbiol, 2024, 62(2): e0073223. PMCID: PMC10865822. DOI: 10.1128/jcm.00732-23 .
[33]
Sun Y, Zhang J. Helicobacter pylori recrudescence and its influencing factors[J]. J Cell Mol Med, 2019, 23(12): 7919-7925. PMCID: PMC6850920. DOI: 10.1111/jcmm.14682 .

Footnotes

所有作者均声明无利益冲突。

PDF(870 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/